Skip to main content
Premium Trial:

Request an Annual Quote

Infocom, Ariadne Genomics to Integrate Software for Protein, DNA Chip Data Analysis

NEW YORK, Oct. 20 (GenomeWeb News) - Infocom and Ariadne Genomics today said that Ariadne will integrate Infocom's new gene network analysis software AutoNet Finder with its PathwayStudio Central client-server pathway-analysis software.


With the addition of AutoNet Finder, to scientists using Pathway Studio Central will be able to "infer regulatory networks from gene expression data and validate them through comparison with ResNet database of functional relationships compiled from literature," which is a part of PathwayStudio Central, the companies said.


"We plan to provide a collection of inference algorithms aimed at the reconstruction of regulatory networks from microarray data," Ilya Mazo, president at Ariadne Genomics, said in a statement. "For our clients, it will simplify the analysis of complex data sets and help to generate new insights into the mechanisms of cell regulation."


Auto Net Finder will be available as a network inferring module for Ariadne Genomics Pathway analysis products for an additional fee, the firms said.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.